ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck & Co., Inc clinical trials

Also known as MSD.

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,453 studies whose lead sponsor is Merck & Co., Inc or one of 32 companies grouped under it. 145 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 18, 2026.

Our grouping of 32 registry names, not the registry’s. See them and correct one ↓

Compare Merck with AstraZeneca and Bristol-Myers Squibb →

Pipeline: 85 programs

Each counted once: 85 with a study Merck & Co., Inc leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 36 with the most live studies.

Program
sacituzumab tirumotecanPhase 3 · Merck & Co., Inc: Registration · 28 live · Carcinoma, Non-Small-Cell Lung · primary completion May 2027☆ Track
belzutifanPhase 3 · 15 live · Carcinoma, Renal Cell · primary completion Feb 2027☆ Track
tulisokibartPhase 3 · Merck & Co., Inc: Phase 3 · 10 live · Crohn Disease · primary completion Feb 2027☆ Track
ifinatamab deruxtecanPhase 3 · Merck & Co., Inc: Phase 3 · 10 live · Small Cell Lung Carcinoma · primary completion Jun 2027☆ Track
intismeran autogenePhase 3 · Merck & Co., Inc: Phase 3 · 9 live · Carcinoma, Non-Small-Cell Lung · primary completion Apr 2027☆ Track

31 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Merck & Co., Inc’s own registered studies; “Merck & Co., Inc says” is its pipeline, which lists phases by indication. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

8 of Merck’s programs have a dated deal behind them: 4 brought in, 4 developed with a partner. Each from the companies’ own releases and filings, linked; the registry does not record them.

Brought in 4

Developed with a partner 4

What it is testing

The drugs Merck & Co., Inc’s studies test, most open studies first — 388 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 388; every drug is on its own page, and each page lists its sponsors.

Coming up

60 of Merck & Co., Inc’s studies under way reach primary completion within a year, 19 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 5D
  3. 6J’27
  4. 6F
  5. 4M
  6. 4A
  7. 7M
  8. 6J
  9. 7J
  10. 2A
  11. 4S
  12. 6O
  13. 2N

The 12 nearest

Show 7 more

Add all 60 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting14

Show 9 more

All 2,453 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1456%Recruiting 129 · Not yet recruiting 16
  • Under way, not recruiting1084%
  • Completed1,81274%
  • Stopped early37815%Terminated 324 · Withdrawn 53 · Suspended 1
  • Status unknown or other10<1%No longer available 4 · Status unknown 4 · Approved for marketing 2

Phase

Where

Over the years

  1. 07
  2. 17908
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 8626

By the year each study started; 544 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Merck & Co., Inc.

  • Merck Sharp & Dohme LLC
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2,167 studies →
  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jan 21, 2015 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    65 studies →
  • ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
    Acquired — became part of Merck & Co., Inc, Jan 16, 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    32 studies →
  • Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
    Acquired — became part of Merck & Co., Inc, Nov 19, 2021 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    26 studies →
  • Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jan 21, 2015 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    19 studies →
  • Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jul 26, 2016 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    15 studies →
  • Verona Pharma plc
    Acquired — became part of Merck & Co., Inc, Oct 7, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    13 studies →
  • Schering-Plough
    Acquired — became part of Merck & Co., Inc, Nov 3, 2009 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    10 studies →
  • Cidara Therapeutics Inc.
    Acquired — became part of Merck & Co., Inc, Jan 7, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    9 studies →
  • Themis Bioscience GmbH
    Acquired — became part of Merck & Co., Inc, Jun 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Apr 2, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jul 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • EyeBiotech Ltd.
    Acquired — became part of Merck & Co., Inc, Jul 2024 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Sep 2007 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jan 21, 2015 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Dec 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jun 16, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jan 11, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Dec 2014 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
    Acquired — became part of Merck & Co., Inc, Oct 7, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Jan 7, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Mar 11, 2024 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, May 5, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • Terns, Inc.
    Acquired — became part of Merck & Co., Inc, May 5, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • MSD Italia S.r.l.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • MSD R&D (China) Co., Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • MSD Pharmaceuticals LLC
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Acquired — became part of Merck & Co., Inc, Dec 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • EyebioKorea, Inc.
    Acquired — became part of Merck & Co., Inc, Jul 2024 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • MSD Belgium BVBA
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Verona Pharma Inc
    Acquired — became part of Merck & Co., Inc, Oct 7, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • MSD Korea Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Related but not counted here: Dupont Merck (affiliate).

Focus areas

Conditions Merck & Co., Inc leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Show all 79 areas

Studies

Recruiting first, then most recently updated. Showing 50 of 2,453. Browse all 2,453 →